Sandoz Wants the Rest of Systemix
Do biotech's investors win when a large drug company buys a majority share as opposed to the whole banana? Not usually. Here we've charted the share prices at which acquirors bought shares in their majority owned affiliates, Sandoz's unsolicited bidto buy the rest of SyStemix for $17 a share represents an enormous let-down for investors.
You may also be interested in...
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.
Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.